CytoDyn Inc. (CYDY) stock
Close on Oct 19, 2026Market cap $345.56MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Aug 31, 2026
Valuation
- Market cap
- $345.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$57.10M
- EPS, diluted
- -$0.04
- Book value per share
- -$0.07
- Diluted shares
- 1.38B
Trading
- Previous close
- $0.23
- Open
- $0.23
- Day's range
- $0.23 – $0.29
- Volume
- 6,475,195
- Average volume (20 days)
- 1,921,225
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CYDY | S&P 500 | Difference | CYDY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +17.0% | +0.6% | +16.3 pts | ||
| 3 months | +17.7% | +3.4% | +14.3 pts | ||
| Year to date | -10.7% | +13.3% | −24.0 pts | ||
| 1 year | -6.3% | +16.6% | −22.9 pts | ||
| 3 years | +56.3% | +86.4% | −30.1 pts | +16.0% | +23.1% |
| 5 years | -82.1% | +81.9% | −164.0 pts | -29.1% | +12.7% |
| 10 years | -62.1% | +318.9% | −381.0 pts | -9.3% | +15.4% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CytoDyn filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About CytoDyn
Pharmaceutical Preparations
CytoDyn Inc. is a clinical-stage biotechnology firm that focuses on developing and potentially commercializing targeted therapies for oncology indications. Its primary investigational asset is leronlimab, a humanized monoclonal antibody designed to bind the CCR5 receptor, which is associated with tumor development, cellular migration, and immune modulation. The company investigates leronlimab primarily for solid tumors, including relapsed or refractory metastatic colorectal cancer and metastatic triple-negative breast cancer, alongside preclinical evaluations for glioblastoma multiforme. As a development-stage biopharmaceutical organization without approved commercial products, CytoDyn does not sell therapies to conventional commercial customers; instead, its clinical programs serve cancer patients enrolled in trials and expanded access protocols.
Company profile, executives and historyCytoDyn stock: common questions
What is CytoDyn's stock price?
CYDY closed at $0.25 on Oct 19, 2026, up 9.53% on the day.
What is CytoDyn's market cap?
CytoDyn was worth $345.56M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CYDY's P/E ratio?
CytoDyn lost money over the twelve months to Aug 31, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
Does CytoDyn pay a dividend?
No. CytoDyn has not paid a cash dividend over the last twelve months.
How has CYDY stock performed over the past year?
Including dividends, CYDY returned -6.3% over the past year, against +16.6% for the S&P 500.
Who are CytoDyn's competitors?
Companies most similar to CytoDyn by business, industry and size include CTMX, CBIO, SNDX, CRBP, CNTX.
See a number that looks wrong?